Physician profile
Samuel V King
NPI 1295800613
$4,225.83
in general payments reported to CMS, 2019-2025
36 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $832 · 2021: $927 · 2022: $1,023 · 2023: $222 · 2024: $35.53 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $564.49 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $554.23 | 2019-2023 | |
| Amgen INC. | $528.72 | 2019-2023 | Repatha |
| Pfizer INC. | $455.55 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $322.35 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $232.66 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $205.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.26 | 2020-2021 | |
| Abbott Laboratories | $142.87 | 2019-2025 | Assurity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.13 | 2019-2023 | Jardiance |
| Biotronik INC. | $115.67 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.40 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $77.39 | 2019-2025 | Avvigo Guidance System, Bodyguardian |
| Esperion Therapeutics, INC. | $55.58 | 2020-2022 | |
| Terumo Medical Corporation | $47.93 | 2022-2025 | Metacross Otw, Optitorque, Glidewire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $47.55 | 2019 | |
| Daiichi Sankyo INC. | $46.30 | 2020-2023 | Injectafer |
| Portola Pharmaceuticals, LLC | $45.65 | 2020 | |
| Alnylam Pharmaceuticals INC. | $45.38 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $43.74 | 2019-2020 | |
| Getinge USA Sales, LLC | $41.37 | 2025 | Cardiosave Rescue |
| Regeneron Healthcare Solutions, INC. | $39.89 | 2019 | |
| Medicomp INC | $34.62 | 2021 | |
| Bardy Diagnostics, INC. | $25.66 | 2019-2022 | |
| Allergan, INC. | $23.52 | 2020 | |
| Atricure, INC. | $20.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.23 | 2023 | |
| Horizon Therapeutics Plc | $17.30 | 2020 | |
| Amarin Pharma, INC. | $15.45 | 2019 | |
| Cardiva Medical, INC. | $15.44 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Astellas Pharma US INC | $14.85 | 2020 | |
| Cardinal Health 200 LLC | $14.63 | 2020 | |
| Baudax Bio INC. | $14.46 | 2020 | |
| G Medical Diagnostic Services, INC. | $14.26 | 2022 | |
| Cashflow Solutions, LLC | $13.06 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Cvrx, INC. | $12.28 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.